Benzinga | Apr 15, 2021 04:09PM EDT

Qorvo Biotechnologies Awarded $24.4M National Institutes Of Health Contract To Scale Point-of-Care COVID-19 Antigen Testing

Qorvo(r) (NASDAQ:QRVO), a leading provider of innovative radio frequency (RF) solutions that connect the world, has been awarded a $24.4 million contract with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADxSM) initiative. The contract, awarded to Qorvo Biotechnologies, a wholly owned subsidiary of Qorvo, helps advance the production and market launch of the Qorvo Omnia(tm) diagnostic test platform.